Cargando…
Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease
BACKGROUND AND AIM: Interleukin-21 (IL-21) is primarily a T cell-derived cytokine; it is upregulated in patients with Crohn's Disease (CD) and could be a potential new therapeutic target in CD. METHODS: In human material, IL-21 and IL-21R expression was investigated by in situ hybridization (IS...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914125/ https://www.ncbi.nlm.nih.gov/pubmed/29849593 http://dx.doi.org/10.1155/2018/5962624 |
_version_ | 1783316654936031232 |
---|---|
author | Holm, Thomas Lindebo Tornehave, Ditte Søndergaard, Henrik Kvist, Peter Helding Sondergaard, Bodil-Cecilie Hansen, Lene Hermit, Mette Brunsgaard Holgersen, Kristine Vergo, Sandra Frederiksen, Klaus Stensgaard Haase, Claus Lundsgaard, Dorthe |
author_facet | Holm, Thomas Lindebo Tornehave, Ditte Søndergaard, Henrik Kvist, Peter Helding Sondergaard, Bodil-Cecilie Hansen, Lene Hermit, Mette Brunsgaard Holgersen, Kristine Vergo, Sandra Frederiksen, Klaus Stensgaard Haase, Claus Lundsgaard, Dorthe |
author_sort | Holm, Thomas Lindebo |
collection | PubMed |
description | BACKGROUND AND AIM: Interleukin-21 (IL-21) is primarily a T cell-derived cytokine; it is upregulated in patients with Crohn's Disease (CD) and could be a potential new therapeutic target in CD. METHODS: In human material, IL-21 and IL-21R expression was investigated by in situ hybridization (ISH) and immunohistochemistry (IHC) in noninflammatory bowel disease (non-IBD) controls and patients with CD. The pathologic role of IL-21 was examined in murine models of T cell-dependent and T cell-independent colitis, either with a neutralizing monoclonal antibody against IL-21 or with the transfer of CD4(+)CD45RB(high)IL-21R(−/−) T cells. Colonic pathology was examined by endoscopy, histopathology, IHC, ELISA, and Luminex. RESULTS: In the human intestine, IL-21 and IL-21R mRNA and protein-expressing cells were observed in the mucosa, in lymphoid aggregates of submucosa in non-IBD controls, and in lymphoid aggregates of muscularis externa in patients with CD. IL-21 expression was most abundant in germinal centers (GCs) of the lymphoid aggregates, and IL-21R expression assessed semiquantitatively, was significantly higher in patients with CD compared to non-IBD controls. Following prophylactic and interventive anti-IL-21 mAb treatment in the adoptive transfer (AdTr) model, clinical and pathological parameters were significantly reduced. The most persistent finding was a reduction in colonic infiltrating neutrophils. As well, Rag2(−/−) mice receiving CD4(+)CD45RB(high)IL-21R(−/−) T cells developed less severe colitis compared to Rag2(−/−) mice receiving CD4(+)CD45RB(high)IL-21R(+/+) T cells. No effect of reduced IL-21 signalling was observed in T cell-independent colitis. CONCLUSION: Our study shows that patients with CD have significant expression of IL-21 and IL-21R in the gut. As well, we show that neutralization of IL-21 in experimental T cell-driven colitis is associated with a reduction in clinical and pathological findings. This amelioration seems to be associated with a reduction in colon-infiltrating neutrophils. |
format | Online Article Text |
id | pubmed-5914125 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-59141252018-05-30 Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease Holm, Thomas Lindebo Tornehave, Ditte Søndergaard, Henrik Kvist, Peter Helding Sondergaard, Bodil-Cecilie Hansen, Lene Hermit, Mette Brunsgaard Holgersen, Kristine Vergo, Sandra Frederiksen, Klaus Stensgaard Haase, Claus Lundsgaard, Dorthe Gastroenterol Res Pract Research Article BACKGROUND AND AIM: Interleukin-21 (IL-21) is primarily a T cell-derived cytokine; it is upregulated in patients with Crohn's Disease (CD) and could be a potential new therapeutic target in CD. METHODS: In human material, IL-21 and IL-21R expression was investigated by in situ hybridization (ISH) and immunohistochemistry (IHC) in noninflammatory bowel disease (non-IBD) controls and patients with CD. The pathologic role of IL-21 was examined in murine models of T cell-dependent and T cell-independent colitis, either with a neutralizing monoclonal antibody against IL-21 or with the transfer of CD4(+)CD45RB(high)IL-21R(−/−) T cells. Colonic pathology was examined by endoscopy, histopathology, IHC, ELISA, and Luminex. RESULTS: In the human intestine, IL-21 and IL-21R mRNA and protein-expressing cells were observed in the mucosa, in lymphoid aggregates of submucosa in non-IBD controls, and in lymphoid aggregates of muscularis externa in patients with CD. IL-21 expression was most abundant in germinal centers (GCs) of the lymphoid aggregates, and IL-21R expression assessed semiquantitatively, was significantly higher in patients with CD compared to non-IBD controls. Following prophylactic and interventive anti-IL-21 mAb treatment in the adoptive transfer (AdTr) model, clinical and pathological parameters were significantly reduced. The most persistent finding was a reduction in colonic infiltrating neutrophils. As well, Rag2(−/−) mice receiving CD4(+)CD45RB(high)IL-21R(−/−) T cells developed less severe colitis compared to Rag2(−/−) mice receiving CD4(+)CD45RB(high)IL-21R(+/+) T cells. No effect of reduced IL-21 signalling was observed in T cell-independent colitis. CONCLUSION: Our study shows that patients with CD have significant expression of IL-21 and IL-21R in the gut. As well, we show that neutralization of IL-21 in experimental T cell-driven colitis is associated with a reduction in clinical and pathological findings. This amelioration seems to be associated with a reduction in colon-infiltrating neutrophils. Hindawi 2018-04-10 /pmc/articles/PMC5914125/ /pubmed/29849593 http://dx.doi.org/10.1155/2018/5962624 Text en Copyright © 2018 Thomas Lindebo Holm et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Holm, Thomas Lindebo Tornehave, Ditte Søndergaard, Henrik Kvist, Peter Helding Sondergaard, Bodil-Cecilie Hansen, Lene Hermit, Mette Brunsgaard Holgersen, Kristine Vergo, Sandra Frederiksen, Klaus Stensgaard Haase, Claus Lundsgaard, Dorthe Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease |
title | Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease |
title_full | Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease |
title_fullStr | Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease |
title_full_unstemmed | Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease |
title_short | Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease |
title_sort | evaluating il-21 as a potential therapeutic target in crohn's disease |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914125/ https://www.ncbi.nlm.nih.gov/pubmed/29849593 http://dx.doi.org/10.1155/2018/5962624 |
work_keys_str_mv | AT holmthomaslindebo evaluatingil21asapotentialtherapeutictargetincrohnsdisease AT tornehaveditte evaluatingil21asapotentialtherapeutictargetincrohnsdisease AT søndergaardhenrik evaluatingil21asapotentialtherapeutictargetincrohnsdisease AT kvistpeterhelding evaluatingil21asapotentialtherapeutictargetincrohnsdisease AT sondergaardbodilcecilie evaluatingil21asapotentialtherapeutictargetincrohnsdisease AT hansenlene evaluatingil21asapotentialtherapeutictargetincrohnsdisease AT hermitmettebrunsgaard evaluatingil21asapotentialtherapeutictargetincrohnsdisease AT holgersenkristine evaluatingil21asapotentialtherapeutictargetincrohnsdisease AT vergosandra evaluatingil21asapotentialtherapeutictargetincrohnsdisease AT frederiksenklausstensgaard evaluatingil21asapotentialtherapeutictargetincrohnsdisease AT haaseclaus evaluatingil21asapotentialtherapeutictargetincrohnsdisease AT lundsgaarddorthe evaluatingil21asapotentialtherapeutictargetincrohnsdisease |